RECURSION PHARMACEUTICALS INC. - CLASS A COMMON S

Recursion to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8

03 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry

20 Dec 2023 06:59:00 By Nasdaq GlobeNewswire

Bayer and Recursion Focus Research Collaboration on Oncology

09 Nov 2023 08:41:30 By Nasdaq GlobeNewswire

Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology

09 Nov 2023 07:01:00 By Nasdaq GlobeNewswire

Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results

09 Nov 2023 06:58:00 By Nasdaq GlobeNewswire

Recursion to Participate in Upcoming Investor Conference

02 Nov 2023 07:05:00 By Nasdaq GlobeNewswire

Recursion to Participate in Upcoming Investor Conferences

05 Sep 2023 15:30:00 By Nasdaq GlobeNewswire

Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection

05 Sep 2023 06:59:00 By Nasdaq GlobeNewswire

Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds

08 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results

08 Aug 2023 06:58:00 By Nasdaq GlobeNewswire

Recursion to Participate in Upcoming Investor Conference

01 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships

26 Jul 2023 17:58:00 By Nasdaq GlobeNewswire

Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery

12 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

Recursion Celebrates Opening of Its Canadian Headquarters in Toronto with Government Officials and the Biotech Ecosystem

26 Jun 2023 10:48:04 By Nasdaq GlobeNewswire

Recursion’s Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation has Fully Enrolled

13 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Recursion to Participate in Upcoming Investor Conferences

01 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

Altitude Lab Relocates to Gateway’s BioHive Hub

25 May 2023 15:00:00 By Nasdaq GlobeNewswire

Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results

08 May 2023 07:14:39 By Nasdaq GlobeNewswire

Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities

08 May 2023 06:59:00 By Nasdaq GlobeNewswire